Monthly update of U.S. Food and Drug Administration (FDA) approvals impacting the workers' compensation industry. myMatrixx's report includes new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and newly available generics in the last 12 months.
Monthly Drug News
US WorldMeds and Adamis Pharmaceuticals announced the launch of ZIMHI™ (naloxone hydrochloride injection) on March 31, 2022. ZIMHI is an opioid antagonist indicated in adult and pediatric patients for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
Impact to Workers’ Comp
The utilization of opioid medications in workers’ compensation presents the opportunity for a reversal agent to also be prescribed. The expected utilization of ZIMHI would be comparable to existing naloxone products on the market, such as Narcan®.
For any questions about the use of ZIMHI, naloxone, or opioids and potential relatedness to a claim, please consult with your myMatrixx pharmacist.